West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow WST
West Pharmaceutical Services, Inc. (WST) EV/FCF
As of 16 October 2026, West Pharmaceutical Services, Inc. (WST) trades at a EV/FCF of 62.1×. Over the past ten years it has ranged from 34.6× (February 2026) to 138× (January 2017); the current reading is higher than 55% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 41.5× | (52.12%) |
| FY2024 | 86.7× | 41.69% |
| FY2023 | 61.2× | 59.08% |
| FY2022 | 38.5× | (63.40%) |
| FY2021 | 105× | 50.31% |
| FY2020 | 69.9× | 53.30% |
| FY2019 | 45.6× | 16.59% |
| FY2018 | 39.1× | (30.37%) |
| FY2017 | 56.2× | (57.41%) |
| FY2016 | 132× | 141.32% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 58.1× | 48.98% |
| Mar 2026 | 39.0× | (5.96%) |
| Dec 2025 | 41.5× | (15.87%) |
| Sep 2025 | 49.3× | 8.34% |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SOLV Solventum Corporation compare | −167× |
| MDLN Medline Inc. compare | 17.7× |
| COO The Cooper Companies, Inc. compare | 20.0× |
| BDX Becton, Dickinson and Company compare | 20.4× |
| RMD ResMed Inc. compare | 20.7× |
| ALC Alcon compare | 22.3× |
| BAX Baxter International Inc. compare | 25.0× |
| WST West Pharmaceutical Services, Inc. | 62.1× |
| RGEN Repligen Corporation compare | 159× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on WST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement